Senegal has introduced a generic hydroxyurea medication called Drepaf that reduces the cost of sickle cell disease treatment by 50 percent [5].
This price reduction is critical because sickle cell disease disproportionately affects sub-Saharan Africa, where treatment costs often prevent patients from accessing life-saving care.
More than seven million people worldwide are affected by the disease [1]. About 80 percent of these patients live in sub-Saharan Africa [2]. The medical launch event for the new generic drug took place in Dakar [3].
The introduction of Drepaf aims to address high mortality rates among children born with the condition. Approximately 400,000 children are born with sickle cell disease in Africa every year [3]. About 50 percent of those children die before they reach age 10 [4].
Hydroxyurea is used to manage the symptoms of the disease by reducing the frequency of painful crises and preventing complications. By halving the cost of this therapy [5], health officials intend to improve access for those who previously could not afford the medication.
The availability of the generic version in 2024 represents a shift toward more sustainable healthcare delivery in the region [3]. It provides a viable path for patients to maintain long-term therapy without facing financial ruin.
“The introduction of a generic hydroxyurea medication halves treatment costs for patients in Senegal.”
The deployment of Drepaf in Senegal reflects a broader effort to combat health inequities in sub-Saharan Africa. By transitioning from expensive brand-name drugs to generics, the region can reduce the high childhood mortality rate associated with sickle cell disease, shifting the condition from a likely fatal childhood illness to a manageable chronic disease.
